What Liquid Cartilage™ actually is

Unlike a painkiller, lubricant, or hydrogel filler, Liquid Cartilage™ is a structural implant — one designed not simply to cushion a damaged joint but to give the body a framework within which it can build replacement tissue.

The product is ChondroFiller™, a CE-marked Class 3 medical implant manufactured in Germany and delivered as an injectable collagen-based solution. What makes the mechanism distinctive is what happens after injection: the liquid self-gels within minutes inside the cartilage defect, forming a porous, sponge-like matrix that bonds to the surrounding cartilage. No cutting, no surgical grafts, and — critically — no added cells or growth factors are required.

Once the scaffold is in place, the body takes over. The patient's own stem cells migrate into the collagen matrix, where they gradually mature into cartilage-building cells (chondrocytes) and begin depositing new cartilage tissue. As that process advances, the collagen scaffold is progressively resorbed and replaced by the body's own repair tissue. The regeneration is entirely endogenous.

This distinguishes Liquid Cartilage™ categorically from viscosupplementation (hyaluronic acid), which lubricates but does not attempt structural repair, and from polyacrylamide hydrogel fillers, which occupy space within the joint without triggering tissue regeneration.

In current clinical practice, ChondroFiller™ is placed under real-time ultrasound guidance as an outpatient injection — a pathway that is particularly relevant when considering its application to the hip.

Which hip conditions it targets

Not every patient with hip pain is the same candidate, and that distinction matters here. Published series on ChondroFiller® cover two main clinical presentations in the hip: isolated focal chondral lesions — discrete areas where cartilage has been damaged or lost — and cartilage damage arising secondary to femoroacetabular impingement (FAI).

FAI is a structural condition in which abnormal contact between the ball and socket of the hip joint causes repeated mechanical stress on the cartilage surface. Over time, that contact strips or shears the cartilage at the point of impingement. Because FAI tends to present in younger, physically active patients, it creates a particular clinical challenge: joint replacement is rarely appropriate in this group, yet the cartilage damage is real and progressive. An injectable scaffold pathway that targets focal structural defects is therefore especially relevant for these patients.

Equally important is what the treatment does not cover. Liquid Cartilage™ addresses focal, contained defects — not diffuse, end-stage arthritis affecting the joint broadly. Patients with generalised hip osteoarthritis are a different clinical population, and available sources do not support extending the indication to that group without individual assessment.

Retrieved sources identified no published upper age limit and no defect-size exclusion for the injection approach. Suitability, however, depends on clinical review — typically including MRI assessment of the defect — and varies between individuals. A consultant assessment is needed to determine whether a focal chondral defect of the hip falls within the treatable range.

What the outcomes data shows for the hip

Published multicenter cohort data report a Harris Hip Score (HHS) improvement of approximately +33 points following ChondroFiller® treatment for focal hip cartilage defects. To put that figure in clinical perspective: a difference of 10 points on the HHS is the conventionally accepted threshold for a meaningful patient-reported change. A gain of +33 points sits well above that bar.

Imaging corroborates the functional findings. MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scoring — an MRI-based measure of how completely repair tissue fills and integrates into a cartilage defect — has been reported in the range of 70 to 87 across ChondroFiller®-treated joints. Scores at this level reflect meaningful tissue fill and structural integration at the defect site, rather than superficial coverage.

Because the same collagen scaffold has a more extensive published record in the knee, that evidence provides a useful reference point for biological plausibility. Published series from knee studies report IKDC score improvements of approximately +30 points — a similar order of magnitude to the hip HHS gains. That parallel does not establish equal efficacy across joints, but it is consistent with the same regenerative mechanism operating in different synovial environments.

One methodological point should be stated clearly: these hip figures derive from prospective multicenter observational cohorts. No randomised controlled trial data specific to the hip was identified in the published literature. Prospective multicenter evidence at this effect size is clinically meaningful, but observational design carries inherent limitations — the absence of a control arm, the possibility of patient-selection effects, and individual variation that aggregate figures do not capture.

How the treatment is delivered

For patients weighing up whether to pursue this pathway, the practical reality of the appointment is often as decisive as the clinical evidence.

ChondroFiller® for the hip is delivered as an ultrasound-guided outpatient injection — no general anaesthetic, no surgical incision, and no hospital admission. The appointment typically takes around 30 to 45 minutes from start to finish. Real-time ultrasound imaging is used throughout, allowing the clinician to visualise the joint and guide placement of the collagen scaffold directly to the cartilage defect site. That image-guided precision matters: accurate deposition of the material at the lesion is central to giving the scaffold the best mechanical environment in which to integrate.

Because no general anaesthetic is involved, patients are not subject to the additional preparation, recovery room time, or theatre scheduling that accompanies arthroscopic cartilage procedures — procedures that require full anaesthesia and a separate surgical admission. The injectable pathway is meaningfully less disruptive to daily life, both on the day and in the days that follow.

In terms of procedural experience, over 19,000 ChondroFiller® cases have been performed across multiple international centres. That volume reflects a broad base of real-world clinical use across different joints and patient populations. The proportion of hip-specific cases within this total is not reported separately in available sources, so the figure is best read as an indicator of how widely the injectable scaffold pathway has been adopted rather than as a hip-specific dataset.

How it compares to surgical cartilage options

Three established surgical approaches address focal hip cartilage defects: microfracture, autologous chondrocyte implantation (ACI), and osteochondral allografting. Each requires theatre admission under general or regional anaesthesia. Microfracture penetrates the subchondral bone to draw marrow cells to the defect surface, producing fibrocartilage repair tissue. ACI is a two-stage procedure — cartilage cells are harvested, laboratory-cultured, and reimplanted weeks later. Osteochondral allografting transplants a plug of donor bone and cartilage to reconstruct the lesion. All three involve surgical incisions and post-operative rehabilitation measured in weeks to months.

The procedural contrast with ChondroFiller® is clear: an ultrasound-guided outpatient appointment carries none of the theatre preparation, anaesthetic risk, or surgical wound recovery that these procedures entail. That difference is factual, irrespective of efficacy.

On efficacy, the position is straightforward: no published trial has compared ChondroFiller® directly against any surgical cartilage procedure in the hip. The surgical options carry a longer-term evidence record; ChondroFiller® has an emerging dataset, and its durability over extended follow-up has not yet been established in the published literature. Neither equivalence nor superiority can be claimed in either direction.

Surgery is the appropriate pathway for certain presentations — large lesions, osteochondral involvement, or cases where the subchondral bone is compromised. The injectable approach does not displace surgery for those profiles. Which pathway is suitable depends on defect characteristics, patient health, and activity demands, and that determination belongs to individual clinical assessment rather than to any general rule.

Access, funding, and what the evidence still needs to show

The treatment is entirely self-funded in the UK. There is no NHS pathway and no private medical insurance coverage for ChondroFiller®, so cost enters the decision from the outset. What a given case requires in terms of scaffold volume — and therefore what it costs — varies with the size and extent of the defect; establishing that requires a clinical assessment with MRI review rather than a general estimate.

On the evidence, some important limits deserve plain statement. The published hip data derive from prospective observational cohorts across multiple international centres, not from randomised controlled trials. Observational cohort studies can be clinically meaningful — the Harris Hip Score and MOCART imaging figures discussed in this article come from peer-reviewed publications — but they sit below RCT-level evidence in the standard hierarchy. Granular study-level information, including individual sample sizes and the full range of follow-up durations, is not uniformly reported in the published summaries currently available. The research programme is described as ongoing, and further hip-specific publications are expected to add to the dataset, particularly over longer time horizons and in relation to durability.

Taken together, the evidence is encouraging but still developing. Patients considering this pathway for a focal hip cartilage defect should expect an individualised clinical evaluation — including MRI assessment — to determine whether their presentation is suitable. Further information on that process is available at amsk.co.uk.